Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932646 · ClinicalTrials.gov registry record · Phase 3
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00932646 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 100 participants.
The verdict
NCT00932646, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.
Interventions
- DRUG Placebo
- DRUG BI 1744 (Olodaterol) Low Dose
- DRUG BI 1744 (Olodaterol) Medium Dose
- DRUG Foradil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932646
The ClinicalTrials.gov registry entry for NCT00932646 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00932646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932646 about?
NCT00932646 is a clinical study titled "Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease". The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.
What is the current status of trial NCT00932646?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2009-06.
What interventions are being tested in trial NCT00932646?
The interventions under investigation include: Placebo (DRUG), BI 1744 (Olodaterol) Low Dose (DRUG), BI 1744 (Olodaterol) Medium Dose (DRUG), Foradil (DRUG).
Who is sponsoring clinical trial NCT00932646?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.